Percutaneous closure of patent foramen ovale

Success and outcomes of a low-volume procedure at a rural medical center

Farhan Aslam, A. Elias Iliadis, James C. Blankenship

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: Percutaneous patent foramen ovale (PFO) closure is indicated for recurrent cryptogenic stroke occurring on anticoagulant therapy. Few patients meet this criterion, and the safety of this procedure when performed infrequently is unclear. METHODS: Fifty-two patients with cryptogenic stroke (66%) or transient ischemic attack (34%) undergoing PFO closure from June 2001 to December 2004 were analyzed. CardioSEAL, Amplatzer or Cardia Star devices were used. Patients were discharged on aspirin, clopidogrel or (at the discretion of the neurologist) coumadin for 6 months. RESULTS: The study population was young (mean age 51 years) and included 25 males (48%). Seventeen patients (34%) had atrial septal aneurysms. Balloon-stretched PFO size ranged from 6 to 25 mm. Deployment success was 100%; mild residual shunting persisted in 10 patients (19%) at hospital discharge. Mean length of stay was 1 day. Predischarge complications included bleeding in 4 patients and arrhythmia in 3 patients. At 28-month follow up, 4 patients reported spells of uncertain etiology and 1 had paroxysmal atrial fibrillation. There were no transient ischemic attacks or strokes. One patient died of renal failure and sepsis unrelated to PFO closure. CONCLUSION: Low-volume PFO closure (15/year) can be performed safely and effectively in a moderate-volume interventional laboratory with good short-term clinical results.

Original languageEnglish (US)
Pages (from-to)20-24
Number of pages5
JournalJournal of Invasive Cardiology
Volume19
Issue number1
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Patent Foramen Ovale
clopidogrel
Stroke
Transient Ischemic Attack
Cardia
Warfarin
Anticoagulants
Atrial Fibrillation
Aspirin
Renal Insufficiency
Aneurysm
Cardiac Arrhythmias
Length of Stay
Sepsis
Hemorrhage
Safety
Equipment and Supplies

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Percutaneous closure of patent foramen ovale : Success and outcomes of a low-volume procedure at a rural medical center. / Aslam, Farhan; Iliadis, A. Elias; Blankenship, James C.

In: Journal of Invasive Cardiology, Vol. 19, No. 1, 01.01.2007, p. 20-24.

Research output: Contribution to journalArticle

@article{7a3f41bee4004b77a440588cf790766d,
title = "Percutaneous closure of patent foramen ovale: Success and outcomes of a low-volume procedure at a rural medical center",
abstract = "BACKGROUND: Percutaneous patent foramen ovale (PFO) closure is indicated for recurrent cryptogenic stroke occurring on anticoagulant therapy. Few patients meet this criterion, and the safety of this procedure when performed infrequently is unclear. METHODS: Fifty-two patients with cryptogenic stroke (66{\%}) or transient ischemic attack (34{\%}) undergoing PFO closure from June 2001 to December 2004 were analyzed. CardioSEAL, Amplatzer or Cardia Star devices were used. Patients were discharged on aspirin, clopidogrel or (at the discretion of the neurologist) coumadin for 6 months. RESULTS: The study population was young (mean age 51 years) and included 25 males (48{\%}). Seventeen patients (34{\%}) had atrial septal aneurysms. Balloon-stretched PFO size ranged from 6 to 25 mm. Deployment success was 100{\%}; mild residual shunting persisted in 10 patients (19{\%}) at hospital discharge. Mean length of stay was 1 day. Predischarge complications included bleeding in 4 patients and arrhythmia in 3 patients. At 28-month follow up, 4 patients reported spells of uncertain etiology and 1 had paroxysmal atrial fibrillation. There were no transient ischemic attacks or strokes. One patient died of renal failure and sepsis unrelated to PFO closure. CONCLUSION: Low-volume PFO closure (15/year) can be performed safely and effectively in a moderate-volume interventional laboratory with good short-term clinical results.",
author = "Farhan Aslam and Iliadis, {A. Elias} and Blankenship, {James C.}",
year = "2007",
month = "1",
day = "1",
language = "English (US)",
volume = "19",
pages = "20--24",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "1",

}

TY - JOUR

T1 - Percutaneous closure of patent foramen ovale

T2 - Success and outcomes of a low-volume procedure at a rural medical center

AU - Aslam, Farhan

AU - Iliadis, A. Elias

AU - Blankenship, James C.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - BACKGROUND: Percutaneous patent foramen ovale (PFO) closure is indicated for recurrent cryptogenic stroke occurring on anticoagulant therapy. Few patients meet this criterion, and the safety of this procedure when performed infrequently is unclear. METHODS: Fifty-two patients with cryptogenic stroke (66%) or transient ischemic attack (34%) undergoing PFO closure from June 2001 to December 2004 were analyzed. CardioSEAL, Amplatzer or Cardia Star devices were used. Patients were discharged on aspirin, clopidogrel or (at the discretion of the neurologist) coumadin for 6 months. RESULTS: The study population was young (mean age 51 years) and included 25 males (48%). Seventeen patients (34%) had atrial septal aneurysms. Balloon-stretched PFO size ranged from 6 to 25 mm. Deployment success was 100%; mild residual shunting persisted in 10 patients (19%) at hospital discharge. Mean length of stay was 1 day. Predischarge complications included bleeding in 4 patients and arrhythmia in 3 patients. At 28-month follow up, 4 patients reported spells of uncertain etiology and 1 had paroxysmal atrial fibrillation. There were no transient ischemic attacks or strokes. One patient died of renal failure and sepsis unrelated to PFO closure. CONCLUSION: Low-volume PFO closure (15/year) can be performed safely and effectively in a moderate-volume interventional laboratory with good short-term clinical results.

AB - BACKGROUND: Percutaneous patent foramen ovale (PFO) closure is indicated for recurrent cryptogenic stroke occurring on anticoagulant therapy. Few patients meet this criterion, and the safety of this procedure when performed infrequently is unclear. METHODS: Fifty-two patients with cryptogenic stroke (66%) or transient ischemic attack (34%) undergoing PFO closure from June 2001 to December 2004 were analyzed. CardioSEAL, Amplatzer or Cardia Star devices were used. Patients were discharged on aspirin, clopidogrel or (at the discretion of the neurologist) coumadin for 6 months. RESULTS: The study population was young (mean age 51 years) and included 25 males (48%). Seventeen patients (34%) had atrial septal aneurysms. Balloon-stretched PFO size ranged from 6 to 25 mm. Deployment success was 100%; mild residual shunting persisted in 10 patients (19%) at hospital discharge. Mean length of stay was 1 day. Predischarge complications included bleeding in 4 patients and arrhythmia in 3 patients. At 28-month follow up, 4 patients reported spells of uncertain etiology and 1 had paroxysmal atrial fibrillation. There were no transient ischemic attacks or strokes. One patient died of renal failure and sepsis unrelated to PFO closure. CONCLUSION: Low-volume PFO closure (15/year) can be performed safely and effectively in a moderate-volume interventional laboratory with good short-term clinical results.

UR - http://www.scopus.com/inward/record.url?scp=33846194180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846194180&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 20

EP - 24

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 1

ER -